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THE RIGHT VENTRICLE
The heart is a complex muscular organ that generates blood pressure and therewith blood 
flow in the circulatory system, in order to accommodate transportation of gases, nutrients and 
waste products. The mammalian heart consists of two separate, yet fused pumping systems: 
the right ventricle (RV) and the left ventricle (LV). These pumps are in-series connected by 
the pulmonary vascular bed distally from the RV, and the systemic vascular bed distally from 
the LV. Because of the serial connection, the output in terms of blood volume is equal for both 
ventricles in the absence of shunting. However, in terms of blood pressure, there are marked 
differences between the two ventricles in normal conditions. The resistance of the pulmonary 
vascular bed is far lower than the systemic vascular bed, resulting in a relatively low-pressure 
system in the RV, and a relatively high-pressure system in the LV. The RV was, since an often-
cited study from the 1940’s, for decades long considered to be relatively unimportant for 
maintaining adequate cardiac function.1 Acknowledgement for its clinical relevance increased 
from the 1980’s, until naming the RV “the forgotten chamber” in 1995 removed all doubts 
on its importance.2 Since, our understanding of clinical RV pathophysiology has substantially 
increased. With regards to molecular and cellular mechanisms contributing to failure and 
targeted therapy, however, knowledge about the RV still lags behind that of the LV.3–5 This is 
of particular importance for congenital heart diseases, such as tetralogy of Fallot, in which RV 
failure appears to be a key determinant of clinical status and outcome.
TETRALOGY OF FALLOT
Tetralogy of Fallot is a cyanotic congenital heart disease, named after Étienne Fallot, a French 
physician who described this syndrome in 1888 as “maladie bleue”.6 Dr. Fallot acknowledged in 
his report that he was not the first to describe this syndrome, as multiple descriptions preceded 
that of Fallot. To date, the first known report of TOF was described by Niels Stensen in 1671.7 
This syndrome, schematically displayed in Figure , consists of the following tetralogy:
1. Stenosis of the pulmonary artery (PA)
2. Overriding aorta
3. Ventricular septal defect (VSD)
4. RV hypertrophy
Despite that dr. Fallot was not the first to describe this syndrome, he was the first to describe 
that these four features are not a coincidental gathering of distinct features. As he unequivocally 
showed, all these features result from anterior displacement of the aortopulmonary septum. 
Resulting from this displacement, the pulmonary trunk is narrower than in normal hearts, and 
thus stenotic (feature 1). Furthermore, the aorta is wider and displaced towards the RV. This 
causes both overriding of the aorta (feature 2), and a VSD (feature 3). The fourth feature of 
TOF, the RV hypertrophy, is generally regarded as a secondary anomaly, as it results from the 
increased pressure that the RV has to withstand, because of the pulmonary stenosis and VSD.
Figure 1 | Diagram of tetralogy of Fallot. Reproduced from Blalock A, Taussig HB. JAMA. 1945 May 
19;128(3):189–202 with permission.
The aforementioned defects are not always present in the same degree when comparing 
patients.8 Therefore, TOF can be seen as a disease-spectrum, with accompanying variability in 
clinical presentation and required management. The symptomology is mainly dependent on the 
degree of RV outflow tract (RVOT) obstruction and the resulting balance between pulmonary 
and systemic blood flow. This balance is determined by the direction of the blood flow through 
the VSD, which is in turn dependent on the pressure difference between the RV and the 
left ventricle (LV). This is because blood will always flow from the ventricle with the highest 
pressure, towards the ventricle with the lowest pressure. In normal hearts, the pressure in the 
LV is far higher than the RV. Therefore, when the RVOT and PA obstruction in TOF patients is 
not very severe, the RV pressure will not exceed LV pressure, so there will be a left-right shunt 
through the VSD. However, in the case of severe RVOT/PA obstruction, RV pressure would have 
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exceeded LV pressure, if there would not have been a VSD. Therefore, in such cases, there will be 
a right-left shunt through the VSD. This leads to hypo-perfusion of the pulmonary vasculature 
and cyanosis, which often requires early intervention. This is in contrast with infants who have 
balanced pulmonary and systemic flow, as those infants are usually asymptomatic in early life.
CORRECTIVE SURGERY
Since the early ’50s, TOF can be corrected surgically, by closing the VSD with a patch, 
relieving the RVOT obstruction, and widening the pulmonary artery.9,10 The result of surgery 
is that the pressure load that burdened the RV in early life, due to RVOT obstruction, PA 
stenosis, and VSD, has at least for the most part been resolved. Pressure-loading conditions 
are therefore normal, and there is no more risk of cyanosis. However, the price of widening 
the stenotic PA is that the pulmonary valve (PV) mostly becomes incompetent, resulting in 
pulmonary regurgitation. Thus, the RV that has been exposed to increased pressure load in 
early life, is now exposed to increased volume load. Surgeons attempt to minimize the degree 
of regurgitation by using as little patching over the pulmonary valve annulus (trans-annular 
patch, TAP) as possible, or even without patching (annulus sparing). However, depending 
on the anatomy and the degree of PA stenosis, some degree of regurgitation often remains 
inevitable. Surgery is nowadays preferably performed in early childhood, before the age one 
year, since repair beyond this age has been associated with increased risk of morbidity and 
mortality.11,12 However, primary repair prior to the age of three months has also been described 
as a risk factor for complicated operation or postoperative management in the intensive 
care unit.12 Therefore, if an infant becomes symptomatic and requires early intervention, 
palliative procedures, such as for example aorto-pulmonary shunt palliation, RVOT stenting 
or enlargement, ductus arteriosus stenting or balloon pulmonary valvuloplasty may be needed 
before surgical repair.13–15
LIFE AFTER SURGICAL ‘REPAIR’
Post-surgical patients are usually referred to by ‘repaired tetralogy of Fallot’ patients, 
suggesting that they now have fixed and normal hearts. And indeed, after surgical correction, 
survival into adulthood is excellent, and most children and adolescents experience no or 
little functional impairment.16–18 Even patients with residual lesions, such as pulmonary 
regurgitations, usually do not experience limitations for many years. However, at long term, 
patients remain at increased risk of RV failure and hazardous arrhythmias, both of which often 
lead to substantial morbidity and mortality. Also at long term, patients experience impaired 
physical functioning and quality of life compared to healthy individuals.19–22 Despite surgical 
repair, their hearts have namely been exposed to increased pressure load of the RV in the 
neonatal period prior to surgery, have been exposed to hypoxemia and have been scarred 
during surgery. After surgery, their RV’s are often exposed to abnormal loading conditions 
due to residual lesions as pulmonary valve incompetence, leading to increased RV volume 
load, or RV outflow tract or pulmonary artery obstruction, leading to increased RV pressure 
load. The long term increased risk of RV failure can mostly be attributed to chronic pulmonary 
regurgitation, as prolonged RV volume loading is known to cause progressive RV dilatation, 
dysfunction and also LV dysfunction.23–27 Monitoring RV dilatation and biventricular function 
is therefore reason for periodic cardiac follow-up in these patients.28,29 For assessing RV 
morphology and function, cardiac magnetic resonance (CMR) imaging is the golden standard.30
Pulmonary regurgitation can be treated by either surgical or transcatheter pulmonary valve 
replacement (PVR), which relieves the RV of the increased volume load. This reverses RV 
dilatation and hypertrophy at least partially, and improves biventricular systolic function 
and functional status.31–36 However, treating these patients with PVR also comes at a 
cost: perioperative mortality is low, but not zero, implanted valves are at increased risk of 
endocarditis, and implanted valves deteriorate over time, eventually requiring re-do PVR.34,37,38 
Therefore, performing PVR too early would unnecessarily expose patients to perioperative 
risks and stress and makes future re-do PVR or other interventions more complex. On the 
other hand, when PVR is being performed beyond a certain stage of remodeling, the RV 
will remain dilated and functionally impaired, and patients are at increased risk of death and 
arrhythmia.39,40 Adequate timing of PVR is therefore key. Currently, timing is heavily based 
on the presence of symptoms, QRS duration on electrocardiography, and measures of RV 
dilatation and biventricular function on CMR imaging.28,29,41
As mentioned previously, the occurrence of arrhythmia’s is, besides decreasing ventricular 
function, a common complication in the long-term follow-up of patients with TOF. Atrial 
arrhythmia’s, such as atrial fibrillation or atrial flutter, are frequently seen in these patients 
and are associated with increased hospitalization and mortality.42,43 Furthermore, patients 
are at risk of ventricular tachycardia (VT), ventricular fibrillation (VF) and sudden cardiac 
death (SCD), comprising a significant part of late morbidity and mortality.40,42,44–46 To prevent 
mortality from ventricular arrhythmia, timely interventions are needed, such as PVR in 
the case of pulmonary regurgitation, to prevent progressive adverse remodeling. In some 
selected cases with a high risk of VT in which other treatment options were unsuccessful or 
insufficient, or after the occurrence of VT / VF, an implantable cardioverter-defibrillator (ICD) 
can be implanted. However, just like PVR, ICD implantation comes at a cost, as many patients 
experience distress, decreased quality of life, and anxiety after implantation.47 Therefore, only 
a subset of patients, who are believed to be at substantially increased risk, are considered for 
ICD implantation. Identifying patients who are at high risk is therefore of great importance. 
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For secondary prevention, the treatment algorithm for implanting an ICD is clear, namely that 
in every patient who has experienced cardiac arrest, VT, or unexplained syncope, without 
reversible causes, ICD implantation is indicated.28,29 However, for primary prevention, there 
is no clear treatment algorithm, and therefore ICD implantation for primary prevention can 
still be regarded as ‘controversial’.28 Both the American and European guidelines classify ICD 
implantation for primary prevention as ‘reasonable’, when multiple risk factors are present. 
These risk factors include RV and/or LV dysfunction, non-sustained VT, QRS duration > 180ms, 
extensive RV fibrosis on CMR and inducible VT during electrophysiological (EP) testing.28,29
SEX DIFFERENCES
In the last decades, evidence has been increasing that, in all fields of cardiovascular medicine, 
sex differences exist. These differences include different prevalence and incidence, different 
disease presentation and severity, different mortality, and subsequent differences in optimal 
treatment. This also applies to patients with congenital heart disease.48 Female patients 
experience more symptoms, and are at increased risk to develop pulmonary hypertension, 
compared to male patients.49–51 On the other hand, male patients are at higher risk of 
arrhythmia and mortality, compared to female patients.42,52 In patients with repaired tetralogy 
of Fallot, male patients have lower biventricular ejection fraction, and both heavier and larger 
hearts, even when indexed for body surface area.53,54 Furthermore, the RV of female patients 
with PAH demonstrated better recovery after initiation of treatment, compared to male PAH 
patients, under similar loading conditions and with similar pulmonary vascular resistance.55 
However, despite apparent differences between sexes, guidelines barely provide sex-tailored 
recommendations.28,29
The demonstrated differences between sexes raise the question of whether they arise from 
either beneficial or deleterious effects of sex hormones, or other factors, such as genetic 
differences. Data from a large cardiovascular disease-free cohort have demonstrated that sex 
hormones are at least partially accountable for cardiac sex differences, as increased levels of 
estradiol, or estradiol metabolism, are associated with better RV systolic function.56,57 This is 
confirmed in experimental studies of RV dysfunction, in which estrogen exerts positive effects 
on RV function and testosterone decreases RV function.58–60 However, it remains unknown 
whether these effects of sex-hormones on the RV could lead to new treatment options.
MOLECULAR RIGHT VENTRICULAR REMODELING
While the need for heart failure therapy in congenital heart disease is growing, there is no 
pharmacological treatment available that has been proven to directly and effectively target 
myocardial function.61 Understanding the underlying mechanisms of cardiac adaptation, 
dysfunction and failure is of great importance to be able to develop targeted therapy for 
(right) heart failure. For such studies, cardiac tissue from patients in different stages of disease 
would be the ideal study material. However, for obvious reasons, these tissues are scarce as 
they can only be collected by biopsy, during surgery or post mortem. Furthermore, tissues 
are never collected at standardized stages of disease. Therefore, animal studies have greatly 
contributed to basic cardiology over the past decades. At first, experimental studies were 
mostly focused on the LV, and it was presumed that the knowledge obtained would be easily 
translatable to the RV. However, as we have come to increasingly understand, the RV and LV 
are not identical twins.5 The RV and LV namely have a different embryological origin, as the 
RV originates from the secondary (or anterior) heart field and the LV from the primary heart 
field.62 Furthermore, the RV and LV are designed for different pressure demands, and are 
therefore morphologically different and have specific motion and fiber orientation patterns. 
The LV cardiomyocytes are predominantly oriented in the circumferential direction, whereas 
the RV cardiomyocytes are mostly oriented in the longitudinal direction. Likewise, the LV 
contracts mostly circumferential, whereas longitudinal motion comprises the largest part of 
RV motion. With the increased appreciation of the differences between the RV and the LV, 
experimental research has now increasingly been focusing on the RV. However, within the 
field of experimental RV studies, there is a clear predominance of models of increased RV 
pressure load, such as pulmonary artery banding (PAB) or models of pulmonary hypertension 
(PH).3,63 However, RV volume load is known to induce a different pattern of RV adaptation, 
compared to RV pressure load.64–66 Pressure load induces concentric hypertrophy, fibrosis 
accompanied by diastolic dysfunction, alterations in cardiac lipid composition, compensatory 
enhancement of systolic function and eventually also loss of ventricular capillarisation and 
systolic failure, while volume load induces eccentric hypertrophy with initially stable diastolic 
and systolic function.65,67,68 However, most studies compare pressure load and volume load 
of equal durations, while it is known that volume load causes RV failure not before long-term 
exposure. Considering that patients experience no or little functional impairment within the 
first years of exposure to volume load, while it may induce progressive, severe dysfunction on 
the longer term, it may thus be more appropriate to study volume load of a longer duration to 
better mimic the actual human clinical problem.
An often named mechanistic factor in heart failure is myocardial fibrosis: being excessive 
deposition of extracellular matrix in the myocardium.69,70 Generally, fibrosis is regarded as 
detrimental for both systolic and diastolic function, and is thus considered to be a treatment 
target in various cardiovascular diseases.69,71 In patients with repaired tetralogy of Fallot, 
indirect imaging markers of fibrosis indeed may be elevated.72–75 However, its significance 
in RV failure is by no means clear yet76, as successfully targeting fibrosis in experimental RV 
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pressure load has not necessarily resulted in improved RV function.77 Furthermore, it remains 
unclear what has caused fibrosis, as suggested by imaging markers, in patients with tetralogy 
of Fallot. A causal factor could be increased RV volume load due to pulmonary regurgitation, 
but also surgery at young age and pre-operative RV pressure load could be factors that induce 
fibrosis. To establish the role of fibrosis in the RV’s of patients with tetralogy of Fallot, it is 
therefore of paramount importance to dissect the relative contribution of each potential cause 
of fibrosis, to determine what underlies the temporal development of fibrosis. To do so, animal 
experiments are necessary. Furthermore, it is highly relevant to determine whether novel 
anti-fibrotic therapies might benefit the dysfunctional RV.
AIMS OF THIS THESIS
To address the challenges outlined above in the long-term follow-up of patients with repaired 
tetralogy of Fallot, understanding RV adaptation to chronic abnormal loading is of the essence. 
Therefore, the aims of this thesis were:
• To characterize RV adaptation to chronic abnormal loading. By studying functional and 
molecular characteristics of RV adaptation in animal models, we aim to identify molecular 
pathways involved in the decline towards RV failure, to aid the development of future 
targets of treatment.
• To identify prognostic factors on cardiac magnetic resonance imaging. Prognostic factors 
are essential for the development of risk stratification schemes, to allow a tailored and 
preventive approach for patients with repaired tetralogy of Fallow in long-term follow-
up. Therefore, we aim to assess the predictive value of cardiac magnetic resonance, a 
cornerstone of long-term follow up, in patients with repaired tetralogy of Fallot.
• To study sex differences in RV adaptation to chronic abnormal loading, Currently, it 
remains unknown whether differences between sexes emerge not before puberty or 
already prior to pubertal development, and whether such differences merit a tailored 
approach with regards to cardiac imaging. Therefore, we aim to describe sex differences 
both an imaging-based study in patients with repaired tetralogy of Fallot and an animal 
model of childhood RV pressure load.
OUTLINE OF THIS THESIS
In chapter 2, we first establish what the current state of knowledge iss on experimental volume 
load-induced RV dysfunction. By systematic review, we provide an overview of what is known, 
expose gaps in our knowledge and understanding, and delineate where we should be headed.
In clinical practice, research with humans and in experimental studies, measures of cardiac 
morphology and function are often indexed for subject size, to allow comparison of subjects 
of different sizes. However, there has been little attention to the efficacy of current methods 
of indexing. In chapter 3, the current common practice of normalizing cardiac parameters in 
small animal models is evaluated and optimized. This novel methodology allows better temporal 
assessment of cardiac measures in growing animals as performed in some of the following chapters.
As described previously, imaging-based studies suggest that patients with tetralogy of Fallot 
demonstrate fibrosis. However, what has caused these processes remains unclear. Our 
systematic review in chapter 2 also raises the suggestion that fibrosis might be involved in 
volume load-induced RV dysfunction, but deals with a low amount of evidence with high 
heterogeneity. To assess whether myocardial fibrosis is truly associated with long-term volume 
load, chapter 4 assesses the temporal development of ventricular fibrosis and pro-fibrotic 
signaling in a rat model of long-term cardiac volume load.
In both the development of myocardial fibrosis and pulmonary vascular remodeling in the case 
of pulmonary arterial hypertension, disturbed TGFβ/BMP signaling is a hallmark pathological 
process. Therefore, we aim to target remodeling and fibrosis in the pulmonary vasculature 
and myocardium with juglone, a pharmacological agent that in part inhibits disturbed TGFβ/
BMP signaling, in models of pulmonary arterial hypertension and right ventricular pressure 
load in chapter 5.
While it is clear from literature that sex differences in RV adaptation to abnormal loading 
conditions exist, this has not been investigated nor described in children or young animal 
models. Such models of young animals provide the opportunity to study RV adaptation 
during pubertal development, before exposure to sex hormones begin to differ between 
sexes. Therefore, in chapter 6, pre- and post-pubertal sex differences in RV adaptation are 
investigated in a juvenile rat model of RV pressure load.
To aid future refinement of risk stratification for arrhythmia, chapter 7 describes the 
prognostic value of conventional measures on cardiac magnetic resonance imaging for the 
development of both atrial and ventricular tachyarrhythmia is investigated in a combined 
Dutch and American cohort of patients with repaired tetralogy of Fallot.
In chapter 8, feature-tracking analyses are used to assess patterns of cardiac motion on cardiac 
magnetic resonance imaging. The prognostic value of such measures for the development of 
ventricular tachyarrhythmia and deterioration of ventricular function is investigated in a Dutch 
cohort of patients with repaired tetralogy of Fallot.
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Currently, in both clinical practice and research, little attention is paid to differences between 
sexes, and a tailored approach for males and females is currently lacking. Therefore, differences 
between sexes on cardiac magnetic resonance are investigated in a combined American and 
Dutch cohort of children and adults with repaired tetralogy of Fallot in chapter 9.
In chapter 10, the findings of this thesis are summarized and discussed.
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